ROZEREM (ramelteon) shown to be effective in a first-night-effect model of...( Salt Lake City Data presented at the S...),Health

Salt Lake City Data presented at the SLEEP 2006 20th Anniversary Meeting of the Associated Professional Sleep Societies have shown that ROZEREMTM (ramelteon) reduced time to fall asleep with no evidence of next-day residual effects, including psychomotor and memory effects, in a first-night-effect model of transient insomnia. The results of this double-blind, randomized study were presented as a poster presentation.

"Some medications taken for sleep are associated with lingering effects the next day, which could make performing activities requiring mental sharpness difficult or dangerous," said Gary Zammit, PhD, Director, Sleep Disorders Institute at St. Luke's-Roosevelt Hospital, New York. "These data suggest that ROZEREM can promote sleep in patients with transient insomnia without evidence of next-day psychomotor or memory effects."

Study Design
A total of 289 healthy adults were randomized to receive either ROZEREM 8 mg, 16 mg, or placebo 30 minutes before bedtime in this double-blind, parallel-group study designed to evaluate the efficacy of ROZEREM in a first-night-effect model of transient insomnia. Sleep was assessed with overnight polysomnography (PSG) a test that records brain activity and other body functions during sleep and a patient questionnaire completed the following morning. Patients also completed next-morning residual-effect assessments evaluating potential residual psychomotor or memory impairment.

Results found that ROZEREM was not associated with next-morning residual effects, as measured by Digit Symbol Substitution Test, memory tests for immediate and delayed recall, and visual analog scales that rate patient reports of mood and feeling. Adverse event rates were 12.4 percent, 13.3 percent, and 6.4 percent for the placebo, ROZEREM 8 mg, and ROZEREM 16 mg groups, respectively, with no clinically meaningful changes in laboratory value, vital sign, or electrocardiogram results observed.

The st
'"/>

Contact: Jocelyn M. Gerst
847-769-6889
Ketchum
19-Jun-2006

Page: 1 2
Related medicine news :

1. ROZEREM (ramelteon) showed significant reduction in time to fall asleep
2. FDA approved ROZEREM (ramelteon)
3. Pro-vitamin E shown to be active against breast cancer cells
4. Ultra low-dose estrogen shown safe for post-menopausal women
5. Radiation therapy shown to increase survival in certain lung cancer patients
6. AMITIZA(TM) (lubiprostone) shown effective and well-tolerated in people older than age 65
7. Drug shown to provide much needed alternative therapy for chronic shoulder pain
8. Nexium shown to reduce gastric ulcers in at-risk patients using long-term NSAIDS
9. State board-disciplined physicians more likely to have shown unprofessional behavior in med school
10. Technology for successful aging shown at White House conference
11. Stress echo tests shown to predict cardiac death, illness in higher-risk women